Alchemab Therapeutics
Focus: Alchemab Therapeutics is a UK-based biotechnology company pioneering human-derived antibodies using a novel resiliomics platform to discover therapeutics. The company is at Series A stage, recently securing £25m in funding to advance its pipeline toward clinical development.
Profile data last refreshed 2h ago · AI intelligence enriched 6d ago
Funding Stage
SERIES A
Open Jobs
1
Should You Work at Alchemab Therapeutics?
AI assessmentAlchemab is a pre-revenue, science-first play suited for early-career researchers and dealmakers with high risk tolerance; career viability depends entirely on Series B capital and clinical proof-of-concept.
Why Work Here
- Ground-floor opportunity at a well-funded Series A (£25m raise in July 2026) with a differentiated platform approach using resiliomics and human-derived antibodies, limiting crowding against legacy competitors.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Alchemab Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.